Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say

This article was originally published in SRA

Executive Summary

Using a clinical trial originally designed for safety to support an efficacy superiority claim poses unique challenges that can make reliance upon a single study for regulatory purposes potentially risky.

Advertisement

Related Content

US FDA Approval Versus Patient Access: A Real-World Anecdote
Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Diabetes Treatment Shift Coming? Cleveland Clinic’s Nissen Declares Victory
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments
Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance
Advertisement
UsernamePublicRestriction

Register

PS118713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel